CXCR3 and neoplasm: By pharmacological inhibition of either the PRC2 component EZH2 or DNMT1, it was possible to restore the tumoral CXCR3 ligand epigenetic silencing and therefore enhance CD8+ T-cell trafficking and tumor growth control [103].